Page 56 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

85. Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of
rivastigmine. J Clin Pharmacol 2002;42(5):558-68.
86. Farlow M, Brashear A, Hui S, Schneider L, Unverzagt F, and TSG. The effects of tacrine in
patients with mild versus moderate stage Alzheimer's disease. Research advances in
Alzheimer's disease and related disorders 1995:283-92.
87. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term
tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study
Group. Neurology 1996;47(1):166-77.
88. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of
tacrine therapy depends on apolipoprotein genotype and gender of the subjects with
Alzheimer's disease. Neurology 1998;50(3):669-77.
89. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine
for dementia associated with Parkinson's disease. N Engl J Med 2004;351(24):2509-18.
90. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of
galantamine in probable vascular dementia and Alzheimer's disease combined with
cerebrovascular disease: a randomised trial. Lancet 2002;359(9314):1283-90.
91. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of
Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol
2000;7(2):159-69.
92. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse
pharmacodynamic drug interactions with rivastigmine and twenty-two classes of
medications. Int J Geriatr Psychiatry 2000;15(3):242-7.
93. Feldman H, GauthierS, Hecker J, Vellas B, Subbiah P, Whalen E, et al. Erratum: a 24-week,
randomized, double-blind study of donepezil in moderate to severe alzheimer's disease
(neurology (2001) 57 (613-620)). Neurology 2001;57(11):2153.
94. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int
J Neuropsychopharmacol 2004;7(3):351-69.
95. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with
Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8:109-
116.
96. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved
dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol
2003;60(6):843-8.
97. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to
assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J
Neurol 1999;6(4):423-9.
98. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with
delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc
2003;51(7):937-44.
99. Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donepezil: tolerability and safety in Alzheimer's
disease. Int J Clin Pract 2002;56(9):710-7.
100. Sano M, Wilcock GK, van Baelen B, Kavanagh S. The effects of galantamine treatment on
caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18(10):942-50.
101. Stahl SM, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttime sleep-
related problems during double-blind, placebo-controlled trials of galantamine in patients
with Alzheimer's disease. Curr Med Res Opin 2004;20(4):517-24.

Alzheimer's Drugs Page 56 of 205